Christopher Winrow, PhD, Recursion’s vice president of neuroscience, inside the company’s lab. Recursion marked a milestone in its up to $12 billion artificial intelligence (AI) collaboration with ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Recursion outlines $375M 2026 cash OpEx guidance while advancing first Genentech neuroscience target
"Over the past year, we have reached an important inflection point. We are no longer just discussing the potential of our platform." (CEO, President & Director Najat Khan) "We now have 5 clinical ...
BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Factorial Energy Inc. (“Factorial”) (Nasdaq: FAC), a global leader in solid-state battery technology, today announced that the Company plans to attend the ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results